UPC Analytics
ENDE
Overview · Filed: May 23, 2025

UPC_CoA_446/2025

INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES

AppealsMain AppealCourt of AppealAppealCase Closed
OverviewDecisionsCitationsDocumentsTimeline
Parties

Claimants

  • Boehringer Ingelheim International GmbH
Reps: Joana Piriquito Santos (Piriquito Santos & Associados)

Respondents

  • ZENTIVA PORTUGAL, LDA
Reps: Patrícia Paias (Antas da Cunha ECIJA)
Judges
  • Rian Kalden
  • Ingeborg Simonsson
  • Patricia Rombach
  • Andreas Gustafsson
  • Carola Wagner
Patents
  • EP1830843
  • EP 1 830 843
CPC codes: C07D403/12, A61K31/4178, A61K31/4045, A61K31/496, A61K31/495, A61K47/38, A61K9/08, C07D209/34, A61K9/1623, A61K47/10, A61K31/404, A61K9/0031…

Sector: Organic Chemistry

Outcome
PI granted
Filed: May 23, 2025
First decided: —
Language: English

The Court of Appeal set aside the Lisbon Local Division's refusal to grant provisional measures and ordered a preliminary injunction against Zentiva Portugal prohibiting the making, offering, placing on the market or use of nintedanib products (Nintedanib Zentiva 100mg and 150mg soft capsules) for idiopathic pulmonary fibrosis in 17 UPC Contracting Member States while EP 1 830 843 remains in force. The court held that completion of national HTA/pricing/reimbursement procedures constitutes imminent infringement. Zentiva was ordered to pay EUR 199,000 as an interim award of costs. The request for an information order was denied.

Open on UPC Registry